A nomogram could help to predict patients at risk of Grade 4 neutropenia during treatment, according to a study published in Clinical Genitourinary Cancer.
A nomogram could help to predict patients at risk of Grade 4 neutropenia during treatment, according to a study published in Clinical Genitourinary Cancer.
Nomograms are used in oncology as prediction tools to help patients and physicians make treatment decisions. The device uses an alpha-numeric code to describe something unique about the patient: genetic makeup, tumor makeup, comorbidities, social environment, etc.
Researchers from Tokyo Medical University in Japan studied 112 patients with castration-resistant prostate cancer (CRPC) who were treated with docetaxel-based systemic chemotherapy. Neutropenia is a major adverse event of docetaxel-based chemotherapy and the researchers sought to develop a nomogram for predicting Grade 4 neutropenia during the first cycle of chemotherapy.
More than half (55.4%) of the patients developed Grade 4 neutropenia in the first cycle of docetaxel-based chemotherapy. The researchers noted that there were significant differences in age, baseline white blood cell count, and baseline neutrophil count among patients with non-Grade 4 neutropenia and those with Grade 4 neutropenia.
However, there were not significant differences between the 2 groups when it came to serum prostate-specific antigen level, hemoglobin level, creatinine, albumin, Eastern Cooperative Oncology Group performance status, metastatic sites, extent of disease, and history of external beam radiotherapy to the prostate.
As a result, the researchers determined that age and baseline neutrophil counts were significant independent risk factors for severe neutropenia.
“Age and baseline neutrophil counts were significant independent risk factors for Grade 4 neutropenia,” the authors concluded. “The nomogram to predict it provides useful information for the management of patients with CRPC treated with docetaxel chemotherapy.”
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen